Guggenheim says this little-known cancer stock can more than double from here
Guggenheim applauded CC Oncology's immunotherapy development and "potentially attractive catalyst path."
You are not logged in so some information on this page has been withheld. To see more, please log in or sign up.
CC Oncology
since
auto-detected in 1 stories
60 days ago
page 1 of 1